Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FOLH1 | Q04609 | 3/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | NOD1 | Q9Y239 | 5/20 | 0.42 |
| ▸ | CA2 | P00918 | 5/20 | 0.42 |
| ▸ | CA1 | P00915 | 4/20 | 0.42 |
| ▸ | F2 | P00734 | 1/20 | 0.42 |
| ▸ | RIMKLA | Q8IXN7 | 1/20 | 0.41 |
| ▸ | NAALAD2 | Q9Y3Q0 | 1/20 | 0.41 |
| ▸ | GNPAT | O15228 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.39 |
| ▸ | BLM | P54132 | 1/20 | 0.39 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.39 |
| ▸ | BMP1 | P13497 | 1/20 | 0.38 |
| ▸ | SLC6A5 | Q9Y345 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9074250 | 1.00 | FOLH1 (0.46) | FOLH1KMT2ANOD1CA2CA1 | |
| SCHEMBL24059394 | 0.89 | F2 (0.43) | FOLH1KMT2ANOD1CA2CA1 | |
| SCHEMBL30695077 | 0.88 | FOLH1 (0.46) | FOLH1NOD1 | |
| SCHEMBL468801 | 0.87 | FOLH1 (0.59) | FOLH1NOD1RIMKLANAALAD2GNPAT | |
| SCHEMBL468800 | 0.87 | FOLH1 (0.59) | FOLH1NOD1RIMKLANAALAD2GNPAT | |
| SCHEMBL12648688 | 0.87 | FOLH1 (0.59) | FOLH1NOD1RIMKLANAALAD2GNPAT | |
| SCHEMBL9073934 | 0.86 | NOD1 (0.44) | FOLH1KMT2ANOD1CA2CA1 | |
| SCHEMBL28330170 | 0.84 | NOD1 (0.47) | FOLH1KMT2ANOD1CA2CA1 | |
| SCHEMBL4170252 | 0.84 | KMT2A (0.43) | FOLH1KMT2ANOD1CA2CA1 | |
| SCHEMBL9015874 | 0.84 | KMT2A (0.43) | FOLH1KMT2ANOD1CA2CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170210778-A1 | NOVEL COMPOUNDS | INVIVOGEN SAS (FR) | 2017-07-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170210778-A1 | NOVEL COMPOUNDS | F12, C1R, F11 | FOLH1 4576/4885KMT2A 4320/4885NOD1 890/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.